867291-42-7

Basic information

• Product Name: 4-(4-Morpholinopiperidin-1-yl)aniline
• Synonyms: 4-[4-(4-morpholinyl)-1-piperidinyl]benzenamine;4-(4-Morpholinopiperidin-1-yl)aniline
• CAS NO: 867291-42-7
• Molecular Formula: C₁₅H₂₃N₃O
• Molecular Weight: 261.36262
• Mol File: 867291-42-7.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4-(4-Morpholinopiperidin-1-yl)aniline(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(4-Morpholinopiperidin-1-yl)aniline(867291-42-7)
• EPA Substance Registry System: 4-(4-Morpholinopiperidin-1-yl)aniline(867291-42-7)

Safety Data

• Hazardous Substances Data: 867291-42-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research:
4-(4-Morpholinopiperidin-1-yl)aniline is used as a building block for the synthesis of various compounds, including potential drug candidates. Its specific structural features and biological activities contribute to its potential development into new drugs for various therapeutic applications.
Used in Chemical Research and Analysis:
4-(4-Morpholinopiperidin-1-yl)aniline also serves as a reagent in chemical research and analysis, further highlighting its versatility and importance in the scientific community.

Upstream product

• 350-46-9 4-Fluoronitrobenzene 
• 53617-35-9 4-(piperidin-4-yl)morpholine 
• 867291-41-6 4-(1-(4-nitrophenyl)piperidin-4-yl)morpholine 
• 334942-10-8 4-(piperidin-4-yl)morpholine dihydrochloride 
• 125541-20-0 tert-butyl 4-(morpholin-4-yl)piperidine-1-carboxylate 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 

Relevant articles and documents

WEE1 inhibitors as well as preparation and application thereof

The invention relates to WEE1 inhibitors as well as preparation and application thereof. The present invention relates to compounds of formula (I), or pharmaceutically acceptable salts, solvates, polymorphs or isomers thereof, and their use in the preparation of medicaments for the treatment of diseases associated with WEE1 activity.

CYCLIN-DEPENDENT KINASE INHIBITORS

Described herein are compounds and their pharmaceutically acceptable salts, pharmaceutical compositions thereof, methods of treatment, and medical uses. The compounds described herein are modulators of cyclin-dependent kinases, and are useful in the treatment or alleviation of protein kinase associated disorders, including cancer, infectious diseases, autoimmune diseases, or cardiovascular diseases.

CYCLIN-DEPENDENT KINASE INHIBITORS

Described herein are compounds and their pharmaceutically acceptable salts, pharmaceutical compositions thereof, methods of treatment, and medical uses. The compounds described herein are modulators of cyclin-dependent kinases, and are useful in the treatment or alleviation of protein kinase associated disorders, including cancer, infectious diseases, autoimmune diseases, or cardiovascular diseases.

CYCLIN-DEPENDENT KINASE INHIBITORS

Described herein are compounds and their pharmaceutically acceptable salts, pharmaceutical compositions thereof, methods of treatment, and medical uses. The compounds described herein are modulators of cyclin-dependent kinases, and are useful in the treatment or alleviation of protein kinase associated disorders, including cancer, infectious diseases, autoimmune diseases, or cardiovascular diseases.

CYCLIN-DEPENDENT KINASE INHIBITORS

Described herein are compounds and their pharmaceutically acceptable salts, pharmaceutical compositions thereof, methods of treatment, and medical uses. The compounds described herein are modulators of cyclin-dependent kinases, and are useful in the treatment or alleviation of protein kinase associated disorders, including cancer, infectious diseases, autoimmune diseases, or cardiovascular diseases.

Compound used as ALK (anaplastic lymphoma kinase) inhibitor and application thereof

The invention discloses a compound shown in a formula I, and pharmaceutically acceptable salts, stereoisomers, solvates or predrugs. The symptoms are defined in claim requirements. The compound shownin the formula I has good inhibiting activity on ALK (anaplastic lymphoma kinase), and can be used for preparing medicines for adjusting the activity of the ALK activity or treating the ALK-related diseases, especially nonsmall-cell lung cancer drugs. (The formula I is shown in the attached figure.).

N-CYANOMETHYLAMIDES AS INHIBITORS OF JANUS KINASE

The present invention relates to compounds of general formula (1) that are inhibitors of Janus Kinase (JAK), a family of tyrosine kinases that are involved in inflammatory conditions, autoimmune diseases, proliferative diseases, allergy, transplant reject

Diaminothiazoles

Novel diaminothiazoles of formula (I): [image] are discussed. These compounds selectively inhibit the activity of Cdk4 and are thus useful in the treatment or control of cancer, in particular, the treatment or control of solid tumors. This invention also provides pharmaceutical compositions containing such compounds and methods of treating or controlling cancer, most particularly, the treatment or control of breast, lung, colon, and prostate tumors.